High Pointe Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

High Pointe Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.04M	Sell	26,519 -3,770	-12%	-$315K	1.47%	29
2021 Q4	$2.68M	Buy	30,289 +7,479	+33%	+$617K	1.78%	15
2021 Q3	$1.76M	Hold	22,810	–	–	1.39%	33
2021 Q2	$1.9M	Sell	22,810 -430	-2%	-$34.1K	1.5%	29
2021 Q1	$1.75M	Buy	23,240 +340	+1%	+$27.8K	1.54%	32
2020 Q4	$2.01M	Buy	+22,900	New	+$1.82M	1.9%	16
2018 Q4	–	Sell	-3,950	Closed	-$383K	–	85
2018 Q3	$383K	Sell	3,950 -1,780	-31%	-$178K	0.52%	63
2018 Q2	$540K	Sell	5,730 -60	-1%	-$5.25K	0.77%	50
2018 Q1	$469K	Buy	5,790 +240	+4%	+$20.6K	0.64%	60
2017 Q4	$495K	Hold	5,550	–	–	0.68%	54
2017 Q3	$517K	Buy	5,550 +110	+2%	+$9.72K	0.76%	52
2017 Q2	$494K	Buy	5,440 +1,280	+31%	+$116K	0.77%	52
2017 Q1	$365K	Hold	4,160	–	–	0.58%	56
2016 Q4	$345K	Hold	4,160	–	–	0.57%	53
2016 Q3	$385K	Buy	+4,160	New	+$392K	0.68%	50

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

High Pointe Capital Management's BMRN Position: Q1 2022 in Review

High Pointe Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q1 2022, selling an estimated $315K and leaving 26,519 shares worth $2.04M. The position accounts for 1.47% of the portfolio, ranked #29.

High Pointe Capital Management first reported a position in BMRN in Q3 2016 and has held it in 15 quarters since. The position peaked at $2.68M in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

High Pointe Capital Management held 26,519 shares of BioMarin Pharmaceuticals worth $2.04M as of Q1 2022.
High Pointe Capital Management sold 3,770 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $315K.
BioMarin Pharmaceuticals made up 1.47% of High Pointe Capital Management's portfolio in Q1 2022, its #29 holding.
High Pointe Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 15 quarters since.
High Pointe Capital Management's BioMarin Pharmaceuticals position peaked at $2.68M in Q4 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on High Pointe Capital Management's 13F filing for Q1 2022, filed 10 May 2022.